JERUSALEM (Reuters) - Israeli medical device maker Alpha Tau Medical said on Thursday it raised $26 million in a funding round from investors including Shavit Capital, Medison Ventures and OurCrowd to help finance global clinical trials. Alpha Tau said it has successfully completed its first-in-human clinical trial of Alpha DaRT — a radiation cancer therapy — with squamous cell carcinoma patients from Italy and Israel. It is now conducting trials in other sites, such as its f

Tel Aviv, Israel, June 4, 2020 - Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, is pleased to announce the closing of a Series B equity financing of $26 million. Investors in the round included a mix of existing investors from previous rounds, such as Shavit Capital, Medison Ventures, and OurCrowd, who continue to demonstrate support for the clinical development of Alpha DaRT, as well as a number of new private and family office in

Introduction When 78-year-old Israeli cancer patient Lela Parnes stumbled upon the Alpha DaRT treatment in 2017, with information from a friend of hers, she had just received her third diagnosis of cancer in multiple organs, as part of a long journey that had started in 2013. Lela’s Cancer Treatment Journey Lela had first been diagnosed with cancer in 2013, as a pensionaire enjoying life with her 4 children and 9 grandchildren. Back then, a tumor was detected on her right kid